Steven E. Nissen, MD, MACC
Chief Academic Officer, Heart, Vascular and Thoracic Institute, Cleveland Clinic
Cleveland Clinic, Dept. Cardiovascular Medcn

Printed as of 11/18/2026

Disclosures

Personal Commercial (22)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AbbVie, Inc.	Research/Research Grants ‡ *TRAVERSE*	Significant (>= $5,000)	*Other*
Amgen	Research/Research Grants ‡ *GLAGOV*	Significant (>= $5,000)	*Prevention*
Arrowhead	Research/Research Grants ‡ *CAPITAN Trial*	Significant (>= $5,000)	*Prevention*
Astra Zeneca	Research/Research Grants ‡ *STRENGTH*	Significant (>= $5,000)	*Prevention Vascular Medicine*
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ *Tactic, Crest, Sport*	Significant (>= $5,000)	*Prevention*
Bristol Myers Squibb	Research/Research Grants ‡ *Valor Trial*	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Bristol-Myers Squibb Company	Research/Research Grants ‡ *Valor Trial*	Significant (>= $5,000)	*Valvular Heart Disease*
CRSPR Therapeutics	Research/Research Grants	None ($0)	*Prevention*
Diamedica	Research/Research Grants ‡ *unnamed*	Significant (>= $5,000)	*Prevention*
Doer	Research/Research Grants ‡ *unamed*	Significant (>= $5,000)	*Prevention*
Editas	Research/Research Grants ‡ *Unamed*	Significant (>= $5,000)	*Prevention*
Editor, Current Cardiology Reports (Springer Nature	Other - *Journal Editor*	Significant (>= $5,000)	*General Cardiology*
Eli Lilly	Research/Research Grants ‡ *ACCELERATE. SURMOUNT, ACCLAIM*	Significant (>= $5,000)	*Vascular Medicine Prevention*
Esperion Therapeutics	Research/Research Grants ‡ *CLEAR trial*	Significant (>= $5,000)	*Prevention*
Hygieia	Research/Research Grants ‡ *unamed*	Significant (>= $5,000)	*Prevention*
Kardigan	Research/Research Grants ‡ *KARDINAL. KATALYST*	Significant (>= $5,000)	*Prevention*
Madeigal	Research/Research Grants ‡ *unamed*	Significant (>= $5,000)	*Prevention*
Medtronic	Research/Research Grants	None ($0)	*Arrhythmias and Clinical EP*
Mineralys	Research/Research Grants ‡ *Protocol MLS-101-202 and Protocol MLS-101-203*	Significant (>= $5,000)	*General Cardiology*
New Amsterdam Pharmaceuticals	Research/Research Grants ‡ *TANDEM*	Significant (>= $5,000)	*Prevention*
Novartis	Research/Research Grants ‡ *Lp(a)-Horizons*	Significant (>= $5,000)	*Prevention*
Silence Therapeutics	Research/Research Grants ‡ *Apollo*	Significant (>= $5,000)	*Prevention*

Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Novartis	Other - *Non-compensated speaker*	None ($0)	*Prevention*

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
none	None ($0)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/4/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/4/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/4/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/4/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.